Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1 Trial of Safety and Preliminary Efficacy of Segmental Ablative Radioembolization in Combination With Tremelimumab Plus Durvalumab (MEDI4736) in Patients With Unresectable, or Oligo-Metastatic Cholangiocarcinoma Who Are Not Candidates for Curative Therapy (RAIDEN Trial)

NCT06058663 is registered in ClinicalTrials.gov with Mayo Clinic as lead sponsor.

NCT NCT06058663
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06058663 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1 Trial of Safety and Preliminary Efficacy of Segmental Ablative Radioembolization in Combination With Tremelimumab Plus Durvalumab (MEDI4736) in Patients With Unresectable, or Oligo-Metastatic Cholangiocarcinoma Who Are Not Candidates for Curative Therapy (RAIDEN Trial)
Lead sponsor
Mayo Clinic
Phase
Phase 1
Overall status
Recruiting
Start date
June 6, 2024
Completion date
November 30, 2028
Enrollment
16 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced intrahepatic cholangiocarcinoma, oligometastatic intrahepatic cholangiocarcinoma, stage iii intrahepatic cholangiocarcinoma ajcc v8, stage iv intrahepatic cholangiocarcinoma ajcc v8, unresectable intrahepatic cholangiocarcinoma